#	Pagina
attuale pagina	/open-h2020/projects/216721/index.html
-1	/open-h2020/per-country/be/cen_or_cenelec/index.html

Opendata, web and dolomites

MedicalPhant SIGNED

An advanced 3D simulator to generate 3D-personalized tissue and organ models for diagnosis, planning and pre-treatment of medical vascular interventions

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

MedicalPhant project word cloud

Explore the words cloud of the MedicalPhant project. It provides you a very rough idea of what is the project "MedicalPhant" about.

interventions valida treatment model licensing medical 3d public planning consists patient ce acute environment mark plan emerged fda amount trl6 external simulating industrial provides commercialized penetration globally death diagnosis pathology plus 6 device leaders universities situations surgery company personalized medicalphant commercialize cumulative stakeholders private capacity clinical specialized mri mechanical cash models identical ones diagnostic innovative market simulator internal prototype hospitals roi trials combination associations carry projected cat physical replicate eco diseases certificating validated certification flow patients business 3m organ errors innovation obtain opinion charge vasculature intervention safety cardiovascular printing initial improves estimation

Project "MedicalPhant" data sheet

The following table provides information about the project.

Coordinator	VALIDA INNOVATION SOCIEDAD LIMITADA Organization address address: CALLE HERNAN CORTES, NUM 24 PLANTA 1 PUERTA 1 city: VALENCIA postcode: 46004 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	https://www.validainnovation.com/medicalphant/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-06-01 to 2018-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	VALIDA INNOVATION SOCIEDAD LIMITADA VALIDA INNOVATION SOCIEDAD LIMITADA Organization address address: CALLE HERNAN CORTES, NUM 24 PLANTA 1 PUERTA 1 city: VALENCIA postcode: 46004 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (VALENCIA)	coordinator	50˙000.00

Map

Project objective

VALIDA INNOVATION S.L. emerged with the goal of developing a new 3D simulator that improves the diagnosis, planning and pre-treatment interventions and therefore, improving patient safety and reduction of associated cost to medical errors. This simulator provides a high value in 3D organ models due to its physical mechanical identical to the real ones are able to replicate the patient´s own organ and pathology. The main objective of MedicalPhant project is to develop and commercialized, based on MRI, ECO and CAT studies on patients, a cardiovascular personalized model of external and internal vasculature that allows simulating complex clinical situations due to cardiovascular diseases are the main cause of death globally. Currently, the simulator prototype has a technology level TRL6 and it has been validated in a relevant environment through its implementation in a real case study of cardiovascular surgery providing diagnostic capacity before intervention and patient´s safety after intervention. However, the company needs to work in the implementation of the business model, in the industrial adaptation of our prototype and, in achieving the certification of our 3D simulator to be commercialized. The key stakeholders involved in this project will be hospitals to carry out clinical trials, private, public hospitals and universities to use our technology, specialized organizations in charge of certificating our device to obtain the CE Mark and FDA, key opinion leaders to get a better penetration on the market and patient associations which will contribute to the dissemination of our innovative 3D printing technology in the cardiovascular market. The initial plan to commercialize the MedicalPhant consists in the combination of own production with a partner plus licensing of the technology. According to our estimation, the cumulative cash flow projected by VALIDA INNOVATION at year 5 will amount €10.3M meaning a ROI of 2.6%.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDICALPHANT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEDICALPHANT" are provided by the European Opendata Portal: CORDIS opendata.